Trust Asset Management’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$318K Hold
1,630
0.02% 189
2026
Q1
$366K Hold
1,630
0.03% 164
2025
Q4
$393K Sell
1,630
-64
-4% -$16.4K 0.03% 162
2025
Q3
$464K Hold
1,694
0.03% 149
2025
Q2
$437K Hold
1,694
0.03% 151
2025
Q1
$379K Sell
1,694
-12
-0.7% -$2.8K 0.03% 156
2024
Q4
$390K Hold
1,706
0.03% 155
2024
Q3
$416K Hold
1,706
0.03% 153
2024
Q2
$327K Hold
1,706
0.03% 163
2024
Q1
$338K Hold
1,706
0.03% 161
2023
Q4
$293K Hold
1,706
0.03% 168
2023
Q3
$252K Hold
1,706
0.03% 175
2023
Q2
$373K Hold
1,706
0.04% 143
2023
Q1
$374K Buy
1,706
+64
+4% +$13.9K 0.04% 141
2022
Q4
$342K Hold
1,642
0.04% 148
2022
Q3
$358K Buy
1,642
+116
+8% +$26.4K 0.05% 138
2022
Q2
$320K Buy
1,526
+55
+4% +$11.7K 0.04% 142
2022
Q1
$357K Buy
1,471
+68
+5% +$16.4K 0.04% 145
2021
Q4
$365K Hold
1,403
0.05% 152
2021
Q3
$370K Buy
1,403
+93
+7% +$25.4K 0.05% 146
2021
Q2
$323K Buy
1,310
+137
+12% +$28.8K 0.04% 148
2021
Q1
$228K Buy
1,173
+208
+22% +$41.7K 0.03% 167
2020
Q4
$205K Buy
+965
New +$192K 0.03% 153

Other funds holding RMD

Trust Asset Management's RMD Position: Q2 2026 in Review

Trust Asset Management held its ResMed (RMD) position steady in Q2 2026 at 1,630 shares worth $318K. The position accounts for 0.02% of the portfolio, ranked #189.

Trust Asset Management first reported a position in RMD in Q4 2020 and has held it in 23 quarters since. The position peaked at $464K in Q3 2025. 141 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Trust Asset Management held 1,630 shares of ResMed worth $318K as of Q2 2026.
  • Trust Asset Management left its ResMed share count unchanged in Q2 2026.
  • ResMed made up 0.02% of Trust Asset Management's portfolio in Q2 2026, its #189 holding.
  • Trust Asset Management first reported a position in ResMed in Q4 2020 and has held it in 23 quarters since.
  • Trust Asset Management's ResMed position peaked at $464K in Q3 2025.
  • 141 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Trust Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.